TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15330679
Drug: Estradiol/levonorgestrel (4.4/1.39
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol/levonorgestrel (4.4/1.39 [approved dosage], 4.4/2.74, and 4.5/3.75mg)
Study: 11130523
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (placebo-controlled trials)
Study: 11130523
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (placebo-controlled trials)
Study: 8255408
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of the partial 5‐HT1A agonist ipsapirone
Study: 20961269
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg/day)
Study: 30019249
Drug: Minodronate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minodronate (1 mg/day or 50 mg/4 weeks)
Study: 15357646
Drug: Interferon-beta-1a 24
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-beta-1a 24 MIU (88 microg) administered three times weekly
Study: 15357646
Drug: Interferon-beta-1a 12
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-beta-1a 12 MIU (44 microg) administered daily
Study: 15357646
Drug: Interferon-beta-1a 24
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-beta-1a 24 MIU (88 microg) administered daily
Study: 9833848
Drug: Abacavir-ZDV combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir-ZDV combination therapy (600 mg ZDV)
Study: 18712029
Drug: Petrolatum ointment
Normalized name: GERI PROTECT Petrolatum Ointment
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrolatum ointment
Study: 25375836
Drug: Escitalopram (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (5-20 mg/d)
Study: 23815124
Drug: Nitroglycerin 0.4%
Normalized name: NITROGLYCERIN 0.4% OINT,RTL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin 0.4% ointment (375 mg applied anally every 12 hours for 21 days)
Study: 23815124
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment (375 mg applied anally every 12 hours for 21 days)
Study: 16883264
Drug: Quinapril (Q)
DrugBank: Quinapril (DB00881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinapril (Q) at an average dose of 13 mg/day (n=28)
Study: 16883264
Drug: Valsartan (V)
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan (V) at a dose of 121 mg/day (n=26)
Study: 16883264
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Quinapril and Valsartan (Q+V) at doses of 12 mg/day and 78 mg/day respectively (n=26)
Study: 9240579
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation >8000 IU daily
Study: 9240579
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation >10000 IU daily
Study: 3623736
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg every 12 hours for 7 days
Study: 3623736
Drug: Nalidixic acid
Normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalidixic acid 500 mg every 8 hours for 7 days
Study: 27774990
Drug: Pomalidomide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (both doses)
Study: 30539861
Drug: SOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOX regimen chemotherapy alone
Study: 30539861
Drug: Endostar continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endostar continuous intravenous infusion combined with SOX regimen chemotherapy
Study: 23040422
Drug: Screening followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening followed by intensive multifactorial treatment for people diagnosed with diabetes (n=15)
Study: 31162017
Drug: Doxycycline treatment
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline treatment
Study: 30207587
Drug: Namilumab (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Namilumab (20, 50, 80, and 150 mg via subcutaneous injection)
Study: 28884242
Drug: Low-dose BoNT-A
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose BoNT-A injections at the pretarsal (PT) portion
Study: 28884242
Drug: Low-dose BoNT-A
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose BoNT-A injections at the preseptal (PS) portion
Study: 25778933
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose combination (paracetamol 500 mg and ibuprofen 150 mg)
Study: 25778933
Drug: All combination
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All combination doses
Study: 21748479
Drug: Heavyweight polypropylene
Normalized name: polypropylene (30000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavyweight polypropylene mesh (HWM) (105 g/m(2))
Study: 21748479
Drug: Lightweight polypropylene
Normalized name: polypropylene (30000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lightweight polypropylene mesh (LWM) (28 g/m(2))
Study: 10955702
Drug: L-NAME
Normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME
Study: 7001038
Drug: Fixed drug
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed drug combination of chloroquine and paracetamol (single dose)
Study: 7001038
Drug: Chloroquine and
Normalized name: chloroquine and proguanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine and paracetamol given as separate tablets (extended over 3 days or longer)
Study: 6343259
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg twice daily
Study: 10442510
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg once daily
Study: 6343259
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg once daily
Study: 6343259
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg once daily
Study: 17566314
Drug: Amlodipine/benazepril 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/benazepril 10/20 mg/day
Study: 17566314
Drug: Amlodipine/benazepril 10/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/benazepril 10/40 mg/day
Study: 22571394
Drug: Benazepril 40
Normalized name: benazepril 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 40 mg/day
Study: 12038945
Drug: 4-mg nicotine
Normalized name: nicotine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mg nicotine lozenge
Study: 12038945
Drug: 2-mg nicotine
Normalized name: nicotine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg nicotine lozenge
Study: 12456454
Drug: ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 8 mg IV
Study: 31264757
Drug: Efpeglenatide 4
Normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide 4 mg once weekly
Study: 31264757
Drug: Efpeglenatide 8
Normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide 8 mg once every 2 weeks
Study: 20370845
Drug: Oxycodone prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone prolonged release/naloxone prolonged release
Study: 17547746
Drug: Long-acting corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting corticosteroid injection
Study: 231374
Drug: Intramuscular ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular ACTH (0.5 mg) for 4 days
Study: 31173422
Drug: Vaccine-and-behaviour-change intervention
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-and-behaviour-change intervention (VBC)
Study: 31173422
Drug: Vaccine-only (V)
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-only (V)
Study: 29092012
Drug: NEPA (netupitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEPA (netupitant 300 mg and palonosetron 0.50 mg)
Study: 27885469
Drug: Oral PALO
Normalized name: palo verde pollen extract
DrugBank: Parkinsonia florida pollen (DB11006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PALO (palonosetron 0.50 mg)
Study: 1396064
Drug: Tramadol HCL
Normalized name: tramadol HCl
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol HCL capsule (THC)
Study: 4079660
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered intranasally, double-blind, prior to ethanol ingestion
Study: 12752346
Drug: Famotidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 1.0 mg/kg
Study: 11069316
Drug: ASA 650
Normalized name: ASA 650 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 650 mg q. d.s.
Study: 9014908
Drug: Intravenous Immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Immunoglobulin (IVIg)
Study: 10225757
Drug: Plasma Exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma Exchange followed by Intravenous Immunoglobulin (PE + IVIg)
Study: 8038352
Drug: famotidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine (20 mg b.d.)
Study: 8038352
Drug: cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine (400 mg b.d.)
Study: 8038352
Drug: ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine (150 mg b.d.)
Study: 2902494
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg twice daily for two years or until death
Study: 22289235
Drug: Full kinematic
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full kinematic chain manual and manipulative therapy (MMT) plus exercise
Study: 22289235
Drug: Targeted hip
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted hip manual and manipulative therapy (MMT) plus exercise
Study: 19057270
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/d orally until disease progression or intolerable toxicity
Study: 15909433
Drug: Topical gentamicin
Normalized name: gentamicin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gentamicin
Study: 12824811
Drug: Alcohol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.75 g/kg mixed with diet soda)
Study: 10586830
Drug: Chemoradiation (radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation (radiotherapy combined with systemic chemotherapy)
Study: 25087600
Drug: Agomelatine (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine (25-50 mg/day)
Study: 14744167
Drug: Escitalopram (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10-20 mg/day)
Study: 18322633
Drug: Fluticasone 250
Normalized name: FLUTICASONE 250MCG/BLSTR PO INH ROTADISK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 250 mcg/day
Study: 15731291
Drug: Etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg or 120 mg once a day, Naproxen 500 mg twice daily
Study: 7485925
Drug: Zolpidem 8.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 8.03 mg/placebo
Study: 7485925
Drug: Phenobarbital 100
Normalized name: phenobarbital 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital 100 mg/promethazine 50 mg
Study: 7485925
Drug: Phenobarbital 100
Normalized name: phenobarbital 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital 100 mg/placebo
Study: 8398960
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine injected intravenously
Study: 8398960
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of physiologic saline diluted to 5 ml with 5% glucose (Control)
Study: 12186344
Drug: Frialit-2 implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frialit-2 implants used in bone reconstruction
Study: 10687523
Drug: Flurbiprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (100 mg loading dose and then 50 mg every 6 h)
Study: 8579082
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus rh‐GMCSF (3 micrograms/kg per day i.v.)
Study: 8579082
Drug: Antibiotics alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics alone (ticarcillin‐clavulanate + netilmicin)
Study: 8579082
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus rh‐GMCSF
Study: 1937326
Drug: cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cefuroxime axetil 2 x 500 mg/d
Study: 26359076
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled intravenous analgesia (PCIA)
Study: 26537182
Drug: Metformin (females)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (females)
Study: 26537182
Drug: Metformin (males)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (males)
Study: 24091128
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2) plus Epirubicin (75 mg/m2) plus Bevacizumab (15 mg/kg) every 3 weeks for up to 9 cycles followed by Bevacizumab (15 mg/kg) until disease progression
Study: 24091128
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2) plus Epirubicin (75 mg/m2) plus Bevacizumab (15 mg/kg)
Study: 21846852
Drug: Pegloticase 8
Normalized name: pegloticase 8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegloticase 8 mg biweekly (every 2 weeks)
Study: 21846852
Drug: Pegloticase alternating
Normalized name: Pegloticase
DrugBank: Pegloticase (DB09208)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegloticase alternating with placebo (monthly treatment group)
Study: 15480643
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy at energy level E2=0.44 mJ/mm2
Study: 11738123
Drug: 3-hydroxy-3-methyl-glutaryl coenzyme
Normalized name: 2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor (pravastatin)
Study: 9740604
Drug: Nitrendipine monotherapy
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine monotherapy (average dose 23.4 mg/d)
Study: 26730183
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg
Study: 25458157
Drug: Umeclidinium/vilanterol (UMEC/VI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg
Study: 18344850
Drug: McKenzie therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: McKenzie therapy
Study: 25159291
Drug: Electrophysical agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrophysical agents
Study: 10919680
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate HFA 134a pMDIs (400, 1000, and 2000 microg doses)
Study: 8828766
Drug: Heparin-coated CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated CPB system (HC group)
Study: 8828766
Drug: Heparin-coated oxygenator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated oxygenator and uncoated CPB circuit (HO group)
Study: 3993041
Drug: iodine therapy
Normalized name: IODINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodine therapy with iodine brine
Study: 3993041
Drug: remedial exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: remedial exercise plus iodine brine therapy
Study: 29338568
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose infusion (TDI) of low-molecular weight (LMW) iron dextran (group B)
Study: 22456294
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg administered immediately before meals
Study: 22456294
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg (both regimens)
Study: 12642201
Drug: Combination program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination program or information alone
Study: 10573067
Drug: 100 microg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg/day of G-CSF
Study: 1888645
Drug: Plain aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain aspirin 600 mg four times daily
Study: 1888645
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin 300 mg daily
Study: 1888645
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin 600 mg four times daily
Study: 20217051
Drug: Speech preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech preparation session
Study: 15101858
Drug: Stellate ganglion
Normalized name: Mastocarpus stellatus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stellate ganglion block (SGB) with 10 ml of 1% lidocaine
Study: 9829444
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (CA) 250 mg b.i.d. for 10 days
Study: 9829444
Drug: Ciprofloxacin (CIP)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CIP) 500 mg b.i.d. for 10 days
Study: 7917535
Drug: Etretinate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate (50 mg/day for the first month, followed by 25 mg/day for the following months)
Study: 332345
Drug: Cycle-active therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle-active therapy (methotrexate, cytosine arabinoside, and 6‐thioguanine)
Study: 31752543
Drug: Immunoelectron microscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoelectron microscopy (IEM) with gold‐labelled antibodies against kappa light chains, lambda light chains, transthyretin and amyloid A
Study: 25409112
Drug: Conventional Diagnostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Diagnostic and Treatment Outpatient Medical Care (CONV) approach
Study: 23341418
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (20-minute interventions pre- and post-surgery)
Study: 3441105
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of timolol 0.5% and pilocarpine 2%
Study: 3441105
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of timolol 0.5% and pilocarpine 4%
Study: 21982456
Drug: Real-time automated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time automated electronic medical record alerts for patients with estimated glomerular filtration rates <45 mL/min/1.73 m(2) recommending renal referral and urine albumin quantification if not done within the prior year.
Study: 6742895
Drug: Ice therapy
Normalized name: Ice Therapy
DrugBank: Levomenthol (DB00825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ice therapy
Study: 14756914
Drug: 4800 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4800 microg retinol (vitamin A) + 120 mg Fe + 500 microg folic acid
Study: 14756914
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg Fe + 500 microg folic acid (without vitamin A)
Study: 11359657
Drug: rHuIL-12 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuIL-12 administered by subcutaneous injection at a maintenance dose of 1.25 microg/kg on days 1, 8, and 15 of each 28-day cycle.
Study: 11359657
Drug: IFN-alpha 2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha 2a administered at 9 million units by subcutaneous injection three times per week.
Study: 8503670
Drug: Autohaler inhalation
Normalized name: pirbuterol
DrugBank: Pirbuterol (DB01291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Autohaler inhalation device
Study: 22562730
Drug: Concurrent strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent strength and continuous running training (SCR)
Study: 22562730
Drug: Concurrent strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent strength and interval running training (SIR)
Study: 22562730
Drug: Concurrent strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent strength and continuous cycle ergometer training (SCE)
Study: 19709658
Drug: Non-specific immunomodulation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific immunomodulation therapy (IMT), autologous blood exposed to oxygen/ozone gas mixture by intragluteal injection, administered on day 1, 2, 7, and once a week thereafter for at least 22 weeks.
Study: 19709658
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered to control group (n=74).
Study: 19709658
Drug: Non-specific immunomodulation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific immunomodulation therapy (IMT).
Study: 16296712
Drug: Amlodipine (5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5‐10 mg once daily)
Study: 8151609
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard (20‐40 mg twice daily)